Combined inhibition of BETs and HDACs as a potential epigenetics-based therapy for malignant rhabdoid tumor
Lingyan Zhu, Yuanyuan Li, Yaxian Wen, Jinxuan Wen, Junzhu Zhang, Lingzhao Min, Changsheng Li, Qi Peng, Lisha Wang, Anqi Li, Zebing Liu, Xiaoqiang Wang · 2026
Read Combined inhibition of BETs and HDACs as a potential epigenetics-based therapy for malignant rhabdoid tumor by Lingyan Zhu, Yuanyuan Li, Yaxian Wen, Jinxuan Wen, Junzhu Zhang, Lingzhao Min, Changsheng Li, Qi Peng, Lisha Wang, Anqi Li, Zebing Liu, Xiaoqiang Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13538387.txt.
Description
Lingyan Zhu and colleagues test paired gene-control drugs against malignant rhabdoid tumor in a 2026 study. These rare childhood cancers grow aggressively after loss of a chromatin guard gene, leaving gene regulation badly distorted and survival poor. A focused drug screen across tumor cell lines paired a deacetylase blocker with a reading-protein blocker. Gene profiling, cell cycle checks, and mouse tumor tests traced how the pairing works.
The pair blocked growth together far more strongly than either drug alone, shutting down cell cycle genes and halting division at the first growth gate. Joint action restored two brake proteins, quieted a key growth switch, and silenced its targets. Mouse tumors also shrank more under the pair than under single drugs. The authors nominate dual gene-control blocking as a promising route for this tumor type.
Catalog record
| CREATOR | Lingyan Zhu, Yuanyuan Li, Yaxian Wen, Jinxuan Wen, Junzhu Zhang, Lingzhao Min, Changsheng Li, Qi Peng, Lisha Wang, Anqi Li, Zebing Liu, Xiaoqiang Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44542 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |